)
Moberg Pharma (MOB) investor relations material
Moberg Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved a 76% mycological cure rate in two Phase 3 studies with over 800 patients, demonstrating unprecedented efficacy for a topical nail fungus treatment.
TerclaraⓇ (MOB-015) maintained rapid market leadership in Sweden and Norway, with strong pharmacy sales shares in both value and units.
Commercial partnerships and licensing agreements secured across Europe, Canada, APAC, China, Scandinavia, and Israel, expanding collaboration with Karo Healthcare.
Approved in 14 markets, with launches planned in additional countries and first deliveries outside Nordics expected around year-end.
Strengthened management team and board to support international expansion and upcoming product launches.
Segment performance
In Sweden, TerclaraⓇ holds a 44% value share and 38% unit share in Q2 2026; Norway saw a 42% value share and 37% unit share.
Market leadership established in both Sweden and Norway, with ongoing launches planned in other European and international markets.
Significant events and developments
Awarded 'Launch of the Year 2024' by major Swedish pharmacy chains for revitalizing the category and driving market share.
Nominated for 'Launch of the Year 2025' in Norway by leading pharmacy chains.
Expanded licensing agreements with Karo Healthcare to cover APAC and China.
First European countries approved transition to Karo Healthcare trademarks, enabling launch preparations.
New board members and Chairman appointed at AGM; long-term incentive program implemented.
- Patented topical treatment achieves 76% cure rate and rapid market leadership in Europe.MOB
Investor presentation - Revenue rose and losses narrowed in Q1 2026, with major APAC expansion and Nordic market gains.MOB
Q1 2026 - TerclaraⓇ rapidly became a market leader in Europe with a 76% cure rate and broad approvals.MOB
Stora Aktiedagarna 2026 - TerclaraⓇ leads the European nail fungus market with high cure rates and rapid commercial success.MOB
Investor presentation - TerclaraⓇ achieved Nordic market leadership and set the stage for broad European expansion.MOB
Q4 2025 - North American phase III study missed its endpoint; focus shifts to EU market growth.MOB
Study Update - Interim Phase III data showed low clinical cure rates, increasing U.S. commercialization risk.MOB
Study Update - Terclara led Sweden's Q3 market, fueling growth as U.S. Phase 3 expectations were revised down.MOB
Q3 2024 - Swedish market leadership, European expansion, and SEK 300M impairment after U.S. trial delay.MOB
Q4 2024
Next Moberg Pharma earnings date
Next Moberg Pharma earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)